G

Gentian Diagnostics ASA
OSE:GENT

Watchlist Manager
Gentian Diagnostics ASA
OSE:GENT
Watchlist
Price: 40.8 NOK -0.49% Market Closed
Market Cap: 629.2m NOK
Have any thoughts about
Gentian Diagnostics ASA?
Write Note

Intrinsic Value

The intrinsic value of one GENT stock under the Base Case scenario is 35.5 NOK. Compared to the current market price of 40.8 NOK, Gentian Diagnostics ASA is Overvalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GENT Intrinsic Value
35.5 NOK
Overvaluation 13%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Gentian Diagnostics ASA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GENT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GENT?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Gentian Diagnostics ASA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Gentian Diagnostics ASA

Provide an overview of the primary business activities
of Gentian Diagnostics ASA.

What unique competitive advantages
does Gentian Diagnostics ASA hold over its rivals?

What risks and challenges
does Gentian Diagnostics ASA face in the near future?

Summarize the latest earnings call
of Gentian Diagnostics ASA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gentian Diagnostics ASA.

Provide P/S
for Gentian Diagnostics ASA.

Provide P/E
for Gentian Diagnostics ASA.

Provide P/OCF
for Gentian Diagnostics ASA.

Provide P/FCFE
for Gentian Diagnostics ASA.

Provide P/B
for Gentian Diagnostics ASA.

Provide EV/S
for Gentian Diagnostics ASA.

Provide EV/GP
for Gentian Diagnostics ASA.

Provide EV/EBITDA
for Gentian Diagnostics ASA.

Provide EV/EBIT
for Gentian Diagnostics ASA.

Provide EV/OCF
for Gentian Diagnostics ASA.

Provide EV/FCFF
for Gentian Diagnostics ASA.

Provide EV/IC
for Gentian Diagnostics ASA.

Show me price targets
for Gentian Diagnostics ASA made by professional analysts.

What are the Revenue projections
for Gentian Diagnostics ASA?

How accurate were the past Revenue estimates
for Gentian Diagnostics ASA?

What are the Net Income projections
for Gentian Diagnostics ASA?

How accurate were the past Net Income estimates
for Gentian Diagnostics ASA?

What are the EPS projections
for Gentian Diagnostics ASA?

How accurate were the past EPS estimates
for Gentian Diagnostics ASA?

What are the EBIT projections
for Gentian Diagnostics ASA?

How accurate were the past EBIT estimates
for Gentian Diagnostics ASA?

Compare the revenue forecasts
for Gentian Diagnostics ASA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gentian Diagnostics ASA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gentian Diagnostics ASA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gentian Diagnostics ASA compared to its peers.

Compare the P/E ratios
of Gentian Diagnostics ASA against its peers.

Discuss the investment returns and shareholder value creation
comparing Gentian Diagnostics ASA with its peers.

Analyze the financial leverage
of Gentian Diagnostics ASA compared to its main competitors.

Show all profitability ratios
for Gentian Diagnostics ASA.

Provide ROE
for Gentian Diagnostics ASA.

Provide ROA
for Gentian Diagnostics ASA.

Provide ROIC
for Gentian Diagnostics ASA.

Provide ROCE
for Gentian Diagnostics ASA.

Provide Gross Margin
for Gentian Diagnostics ASA.

Provide Operating Margin
for Gentian Diagnostics ASA.

Provide Net Margin
for Gentian Diagnostics ASA.

Provide FCF Margin
for Gentian Diagnostics ASA.

Show all solvency ratios
for Gentian Diagnostics ASA.

Provide D/E Ratio
for Gentian Diagnostics ASA.

Provide D/A Ratio
for Gentian Diagnostics ASA.

Provide Interest Coverage Ratio
for Gentian Diagnostics ASA.

Provide Altman Z-Score Ratio
for Gentian Diagnostics ASA.

Provide Quick Ratio
for Gentian Diagnostics ASA.

Provide Current Ratio
for Gentian Diagnostics ASA.

Provide Cash Ratio
for Gentian Diagnostics ASA.

What is the historical Revenue growth
over the last 5 years for Gentian Diagnostics ASA?

What is the historical Net Income growth
over the last 5 years for Gentian Diagnostics ASA?

What is the current Free Cash Flow
of Gentian Diagnostics ASA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gentian Diagnostics ASA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gentian Diagnostics ASA

Current Assets 145.8m
Cash & Short-Term Investments 81m
Receivables 23.5m
Other Current Assets 41.2m
Non-Current Assets 41.1m
Long-Term Investments 100k
PP&E 17m
Intangibles 24m
Current Liabilities 21.6m
Other Current Liabilities 21.6m
Non-Current Liabilities 7.8m
Long-Term Debt 7.8m
Other Non-Current Liabilities 72k
Efficiency

Earnings Waterfall
Gentian Diagnostics ASA

Revenue
146.3m NOK
Cost of Revenue
-71.6m NOK
Gross Profit
74.7m NOK
Operating Expenses
-78.6m NOK
Operating Income
-3.9m NOK
Other Expenses
1.9m NOK
Net Income
-2m NOK

Free Cash Flow Analysis
Gentian Diagnostics ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GENT Profitability Score
Profitability Due Diligence

Gentian Diagnostics ASA's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
ROE is Increasing
34/100
Profitability
Score

Gentian Diagnostics ASA's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

GENT Solvency Score
Solvency Due Diligence

Gentian Diagnostics ASA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Gentian Diagnostics ASA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GENT Price Targets Summary
Gentian Diagnostics ASA

Wall Street analysts forecast GENT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GENT is 68.34 NOK with a low forecast of 67.67 NOK and a high forecast of 70.35 NOK.

Lowest
Price Target
67.67 NOK
66% Upside
Average
Price Target
68.34 NOK
68% Upside
Highest
Price Target
70.35 NOK
72% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GENT?

Click here to dive deeper.

Dividends

Gentian Diagnostics ASA
does not pay dividends
Shareholder Yield

Current shareholder yield for GENT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Gentian Diagnostics ASA

Country

Norway

Industry

Health Care

Market Cap

629.2m NOK

Dividend Yield

0%

Description

Gentian Diagnostics ASA is a medical diagnostics company. The company is headquartered in Moss, Ostfold. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

Contact

OSTFOLD
Moss
Bjornasveien 5
+4799339905
www.gentian.com

IPO

2016-12-14

Employees

52

Officers

Executive Chairperson
Dr. Hilja Ibert
Acting CEO, CFO & COO
Mr. Njaal Kind
Chief Scientific Officer
Dr. Aleksandra Havelka
Chief Commercial Officer
Mr. Markus Jaquemar
Head of Innovation & Research
Dr. Ingo Curdt
Head of Product Development
Dr. Tom Nilsen

See Also

Discover More
What is the Intrinsic Value of one GENT stock?

The intrinsic value of one GENT stock under the Base Case scenario is 35.5 NOK.

Is GENT stock undervalued or overvalued?

Compared to the current market price of 40.8 NOK, Gentian Diagnostics ASA is Overvalued by 13%.

Back to Top